ArticleHealth information science and systems2026
Predicting lung cancer survival with attention-based CT slices combination.
Article in Health information science and systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prognosis of Non-Small Cell Lung Cancer (NSCLC) is crucial for enhancing patient care and treatment outcomes. Despite the advancements in deep learning, the task of overall survival prediction in NSCLC has not fully leveraged these techniques, yet. This study introduces a novel methodology for predicting 2-year overall survival (OS) in NSCLC patients using CT scans. Our approach integrates CT scan representations produced by EfficientNetB0 with a soft attention mechanism to identify the most relevant slices for survival risk prediction, which are then analyzed by a risk-assessment network. To validate our method and ensure reproducibility, we employed the public LUNG1 dataset and a smaller private dataset. Our approach was compared to benchmark 3D networks and two variants of our methodology: on the LUNG1 it outperformed the competitors achieving a mean
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.